HYPOGLYCEMIC THERAPY AND CARDIOVASCULAR SAFETY


A.V. Pashentseva, A.F. Verbovoy

Department of Endocrinology, SBEI HPE "Samara State Medical University" of RMPH, Samara
Diabetes mellitus is a chronic, progressive disease that leads to the development of micro- and macrovascular complications. The safety of hypoglycemic therapy is of great importance. The review presents the results of some large-scale studies aimed to the prevention of cardiovascular complications of diabetes mellitus. The problems of the cardiovascular safety against the background of the use of different classes of glucose-lowering drugs are discussed.

Literature


  1. Global status report on noncommunicable diseases 2014. Geneva, World Health Organization.
  2. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br. Med. J. 1998;317:703–13.
  3. Shichiri M., Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kmamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 2000;23(Suppl 2):21–9.
  4. FDA Guidance for Industry. Diabetes mellitus – evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Available from: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatorylnformation/Guidances/ucm071627.pdf
  5. Duckworth W., Abraira C., Moritz T., Reda D., Emanuele N., Reaven P.D., Zieve F.J., Marks J., Davis S.N., Hayward R., Warren S.R., Goldman S., McCarren M., Vitek M.E., Henderson W.G., Huang G.D. Glucose control and vascular complications in veterans with type 2 diabetes. N. Engl. J. Med. 2009;360:129–39.
  6. Ismail-Beigi F., Moghissi E.S. Glycemia management and cardiovascular risk in type 2 diabetes: an evolving perspective. Endocr. Pract. 2008;14:639–43.
  7. The Action to Control Cardiovascular Risk in Diabetes Study Group Effects оf intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 2008;358:2545–59.
  8. Вербовой А.Ф., Барабанова Н.А. Фармакоэпидемиологический анализ терапии сахарного диабета 2-го типа в амбулаторной практике. Проблемы эндокринологии. 2009;4:3–6.
  9. Monami M., Genovese S., Mannucci E. Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes Obes. Metab. 2013;15(10):938–53.
  10. Dluhi R.G, McMahonn G.T. Intensive Glycemic Control in the АССОRD and ADVANCE Trials. N. Engl. J. Med. 2008;358:2630–33.
  11. Woodward M., Patel A., Zoungas S., et al. Does glycemic control offer similar benefits among patients with diabetes in different regions of the world? Results from the ADVANCE trial. Diabetes Care. 2011;34(12):2491–95.
  12. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10–Year Follow–up of Intensive Glucose Control in Type 2 Diabetes. N. Engl. J. Med. 2008;359:1577–89.
  13. Аметов А.С. Сахарный диабет 2 типа. Проблемы и решения: учеб. пос. 2-е изд., перераб. и доп. М., 2014. 1032 с.
  14. Fadini G.P., Avogaro A. Cardiovascular effects of DPP-4 inhibition: Beyond GLP-1. Vascul. Pharmacol. 2011;55(1–3):10–6.
  15. Goto H., Nomiyama T., Mita T., Yasunari E., Azuma K., Komiya K., Arakawa M., Jin W.L., Kanazawa A., Kawamori R., Fujitani Y., Hirose T., Watada H. Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury. Biochem. Biophys. Res. Commun. 2011;405:79–84.
  16. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под редакцией И.И. Дедова, М.В. Шестаковой (7-й выпуск). Сахарный диабет. 2015;18(1S):1–112.
  17. Scirica B.M., Bhatt D.L., Braunwald E., Steg P.G., Davidson J., Hirshberg B., Ohman P., Frederich R., Wiviott S.D., Hoffman E.B., Cavender M.A., Udell J.A., Desai N.R., Mosenzon O., McGuire D.K., Ray K.K., Leiter L.A., Raz I. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med. 2013;369(14):1317–26.
  18. White W., Cannon C.P., Heller S.R., Nissen S.E., Bergenstal R.M., Bakris G.L., Perez A.T., Fleck P.R., Mehta C.R., Kupfer S., Wilson C., Cushman W.C., Zannad F. Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. N. Engl. J. Med. 2013;369:1327–35.
  19. Merck. Merck announces the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) met primary endpoint. www.mercknewsroom.com/news-release/prescription-medicine-news/merck-announces-trial-evaluating-cardiovascular-outcomes-sit.
  20. Wu S., Hopper I., Skiba M., Krum H. Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants. Cardiovasc. Ther. 2014;32(4):147–58.
  21. Дедов И.И., Шестакова М.В., Аметов А.С., Анциферов М.Б., Галстян Г.Р., Майоров А.Ю., Мкртумян А.М., Петунина Н.А., Сухарева О.Ю. Консенсус совета экспертов Российской ассоциации эндокринологов по инициации и интенсификации сахароснижающей терапии у больных сахарным диабетом 2 типа. Сахарный диабет. 2011;4:6–17.
  22. Cleland S.J., Petrie J.R., Ueda S., Elliott H.L., Connell J.M. Insulin as a vascular hormone: implications for the pathophysiology of cardiovascular disease. Clin. Exp. Pharmacol. Physiol. 1998;25(3–4):175–84.
  23. Залевская А.Г., Вербовая Н.И., Родионова Т.И., Викулова О.К., Шестакова М.В. Базальная инсулинотерапия у пациентов с сахарным диабетом типа 2 с неудовлетворительным контролем гликемии на пероральной сахарснижающей терапии: результаты прямого сравнительного исследования аналогов инсулина Лантус и Левемир. Сахарный диабет. 2010;2:106–12.
  24. Скудаев С.А., Вербовая Н.И. Эффективность применения инсулина гларгин в условиях реальной клинической практики: результаты наблюдательной программы LAURUS-2. Проблемы эндокринологии. 2011;6:15–20.
  25. The ORIGIN Trial Investigators. Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia. N. Engl. J. Med. 2012;367:319–28.
  26. Kansagara D., Fu R., Freeman M., Wolf F., Helfand M. Intensive insulin therapy in hospitalized patients: a systematic review. Ann. Intern. Med. 2011;154:268–82.


About the Autors


A.V. Pashentseva- PhD in Medical Scineces, Teaching Assistant at the Department of Endocrinology SBEI HPE "Samara State Medical University" of RMPH, Samara; e-mail: a-pashentseva@yandex.ru
A.F.Verbovoy-Doctor of Medical Sciences, Prof., Head of the Department of Endocrinology SBEI HPE "Samara State Medical University" of RMPH, Samara


Similar Articles


Бионика Медиа